X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs VENUS REMEDIES - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE VENUS REMEDIES CADILA HEALTHCARE/
VENUS REMEDIES
 
P/E (TTM) x 20.1 -4.6 - View Chart
P/BV x 4.8 0.2 2,772.6% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 CADILA HEALTHCARE   VENUS REMEDIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
VENUS REMEDIES
Mar-18
CADILA HEALTHCARE/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs558126 443.2%   
Low Rs36261 591.7%   
Sales per share (Unadj.) Rs116.3301.8 38.5%  
Earnings per share (Unadj.) Rs17.9-24.9 -71.8%  
Cash flow per share (Unadj.) Rs23.12.5 909.0%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.4293.3 29.1%  
Shares outstanding (eoy) m1,023.7412.34 8,296.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.00.3 1,276.1%   
Avg P/E ratio x25.7-3.8 -684.4%  
P/CF ratio (eoy) x19.936.7 54.1%  
Price / Book Value ratio x5.40.3 1,688.3%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6641,154 40,792.9%   
No. of employees `00011.80.9 1,277.7%   
Total wages/salary Rs m18,545393 4,717.6%   
Avg. sales/employee Rs Th10,072.74,026.1 250.2%   
Avg. wages/employee Rs Th1,569.1425.0 369.2%   
Avg. net profit/employee Rs Th1,547.7-331.8 -466.5%   
INCOME DATA
Net Sales Rs m119,0493,724 3,196.7%  
Other income Rs m1,13223 5,031.1%   
Total revenues Rs m120,1813,747 3,207.7%   
Gross profit Rs m28,475395 7,212.5%  
Depreciation Rs m5,388338 1,592.7%   
Interest Rs m911354 257.1%   
Profit before tax Rs m23,308-275 -8,466.4%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,64432 17,860.8%   
Profit after tax Rs m18,292-307 -5,960.2%  
Gross profit margin %23.910.6 225.6%  
Effective tax rate %24.2-11.5 -211.0%   
Net profit margin %15.4-8.2 -186.4%  
BALANCE SHEET DATA
Current assets Rs m82,0052,638 3,109.0%   
Current liabilities Rs m60,7202,305 2,634.7%   
Net working cap to sales %17.98.9 199.9%  
Current ratio x1.41.1 118.0%  
Inventory Days Days73135 54.0%  
Debtors Days Days9846 212.2%  
Net fixed assets Rs m83,7034,871 1,718.5%   
Share capital Rs m1,024123 829.8%   
"Free" reserves Rs m86,4213,496 2,472.2%   
Net worth Rs m87,4453,619 2,416.2%   
Long term debt Rs m25,5511,374 1,859.1%   
Total assets Rs m180,6537,509 2,406.0%  
Interest coverage x26.60.2 11,922.9%   
Debt to equity ratio x0.30.4 76.9%  
Sales to assets ratio x0.70.5 132.9%   
Return on assets %10.60.6 1,683.8%  
Return on equity %20.9-8.5 -246.7%  
Return on capital %22.01.6 1,389.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m42,6830-   
Fx outflow Rs m11,242517 2,176.6%   
Net fx Rs m31,441-517 -6,087.3%   
CASH FLOW
From Operations Rs m9,193514 1,787.1%  
From Investments Rs m-9,737-123 7,909.8%  
From Financial Activity Rs m515-387 -133.0%  
Net Cashflow Rs m-294 -690.5%  

Share Holding

Indian Promoters % 74.8 32.9 227.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.2 4,611.1%  
FIIs % 5.9 0.6 1,017.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 66.4 16.6%  
Shareholders   44,069 20,121 219.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FDC LTD.  UNICHEM LAB  WYETH LTD  DIVIS LABORATORIES  ALEMBIC LTD  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 19, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS